Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy

Journal of Infectious Diseases

Volumn 209, Issue 4, 2014, Pages 500-509

  Naranbhai, Vivek ^a,b   Hill, Adrian V S ^a   Abdool Karim, Salim S ^b   Naidoo, Kogieleum ^b   Abdool Karim, Quarraisha ^b   Warimwe, George M ^a   McShane, Helen ^a   Fletcher, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

combination antiretroviral therapy; HIV; lymphocytes; ML ratio; monocytes; tuberculosis

Indexed keywords

COMBINATION ANTIRETROVIRAL THERAPY; HIV; LYMPHOCYTES; ML RATIO; MONOCYTES; TUBERCULOSIS;

ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MONOCYTES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84893337314     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit494     Document Type: Conference Paper

References (40)

1. Cohen T, Murray M,Wallengren K, Alvarez GG, Samuel EY,Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 2010; 7:e1000296.
2. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev 2010; 12: 183-94.
3. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000; 24:23-9.
4. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11:343-54.
5. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378:57-72.
6. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:45-55.
7. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588-98.
8. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10:489-98.
9. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365:21-31.
10. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
11. Maertzdorf J, Repsilber D, Parida SK, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 2011; 12:15-22.
12. Cunningham RS, Sabin FR, Sugiyama S, Kindwall JA. The role of the monocyte in tuberculosis. Bull Johns Hopkins Hosp 1925; XXXVII: 231-80.
13. Sabin FR, Doan CA, Cunningham RS. Studies of the blood in experimental tuberculosis: the monocyte-lymphocyte ratio; the anemia-leucopenia phase. Trans 22nd Annu Meeting Natl Tuberc Assoc 1926; 22:252-6.
14. Rogers PM. A study of the blood monocytes in children with tuberculosis. N Engl J Med 1928; 198:740-49.
15. Doan CA, Sabin FR. The relation of the tubercle and the monocyte: lymphocte ratio to resistance and susceptibility in tuberculosis. J Exp Med 1930; 52:113-52.
16. Naranbhai V, Abdool Karim Q, Naidoo K, Yende Zuma N, Abdool Karim SS. Task-shifting for antiretroviral treatment is not only effective but also sustainable and improves over time. Lancet 2012; 380:1907-8.
17. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
18. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
19. van Loggerenberg F, Mlisana K,Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008; 3:e1954.
20. Republic of South Africa Department of Health of South Africa, Pretoria, South Africa. South African National Antiretroviral Treatment Guidelines. 2004.
21. Republic of South Africa Department of Health of South Africa, Pretoria, South Africa. South African National Tuberculosis Management Guidelines. 2009.
22. Republic of South Africa Department of Health of South Africa, Pretoria, South Africa. South African National Antiretroviral Treatment Guidelines. 2010.
23. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-501.
24. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-16.
25. Dembele M, Saleri N, Carvalho AC, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis 2010; 14:318-23.
26. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-7.
27. Carpenter E, Fray L, Gormley E. Cellular responses and Mycobacterium bovis BCG growth inhibition by bovine lymphocytes. Immunol Cell Biol 1997; 75:554-60.
28. Denis M, Wedlock DN, Buddle BM. Ability of T cell subsets and their soluble mediators to modulate the replication of Mycobacterium bovis in bovine macrophages. Cell Immunol 2004; 232:1-8.
29. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148:434-46.
30. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003; 1:17-24.
31. Merekoulias G, Alexopoulos EC, Belezos T, Panagiotopoulou E, Jelastopulu DM. Lymphocyte to monocyte ratio as a screening tool for influenza. PLoS Curr 2010; 2:RRN1154.
32. Muller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic regulation of hematopoietic stem cell self-renewal and differentiation. Blood 2002; 100:1302-9.
33. Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc Natl Acad Sci USA 2011; 108:20012-7.
34. Schroeder T. Hematopoietic stem cell heterogeneity: subtypes, not unpredictable behavior. Cell Stem Cell 2010; 6:203-7.
35. Muller-Sieburg CE, Sieburg HB, Bernitz JM, Cattarossi G. Stem cell heterogeneity: implications for aging and regenerative medicine. Blood 2012; 119:3900-7.
36. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature 2010; 465:793-7.
37. Das B, Kashino SS, Pulu I, et al. CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med 2013; 5:170ra13-ra13.
38. Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res 2011; 50:202-12.
39. Kato K. Effect of tuberculin test on monocyte-lymphocyte ratio in children. J Pediatr 1935; 7:238-44.
40. Warimwe GM, Murungi LM, Kamuyu G, et al. The ratio of monocytes to lymphocytes in peripheral blood correlates with increased susceptibility to clinical malaria in Kenyan children. PLoS One 2013; 8:e57320.